Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Denali released some early positive data. Meanwhile its market cap has reduced by 25%.

Denali Is Getting To Be More And More Interesting

Lattice Semiconductor

Realty Income Corp

YETI

Floor & Decor Holdings

It has been a while for sure, but as the old adage says that every dog has his or her day.

5 Sizzling Stocks to Buy Now as the Russell 2000 Continues to Explode Higher

Fate Therapeutics

Moderna

Mirati Therapeutics

Novavax

Seagen

Zai Lab Ltd.

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines appeared first on InvestorPlace.

7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines

The biotech received good news from the FDA concerning one of its pipeline candidates.

Why Denali Therapeutics Stock Popped Today

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). DNL310, Denali's lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a Phase 1/2 study in patients with Hunter syndrome as a potential treatment for both central nervous system (CNS) and peripheral manifestations of the disease.

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

Airbnb

Editas Medicine

CenterPoint Energy

Agios Pharmaceuticals

PetroChina Company Ltd.

LendingTree

Voyager Therapeutics

Zynex Inc

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Airbnb, Centerpoint, Editas and More Friday Afternoon Analyst Calls

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the full year ended December 31, 2020 and provided business highlights.

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

Axcella Health Inc

Codiak Biosciences

Evelo Biosciences Inc

Foghorn Therapeutics

Kaleido Biosciences Inc

Seres Therapeutics

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positive interim results from the ongoing Phase 1/2 study evaluating ETV:IDS (DNL310) as a potential brain-penetrant enzyme replacement therapy for treating both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). The data will be presented later today during a late-breaker session at WORLDSymposium™. Denali management will host an analyst webinar today beginning at 8:00 a.m. Eastern Time to discuss both interim clinical and new preclinical data that will be presented at the conference.

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

– Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time – – Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Nancy Thornberry has joined the Board of Directors, effective January 8, 2021. Ms. Thornberry's extensive biotech leadership and pharmaceutical experience includes more than 30 years of development and discovery work in multiple disease areas, including diabetes and endocrinology.

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced program progress and expected milestones for 2021, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, at 10 a.m. Eastern Time.

Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration

Blink Charging

MongoDB

Ampio Pharmaceuticals Inc

2020 is almost over. Maybe it's time to cash in -- and cash out?

Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today

CRISPR Therapeutics

NantKwest

Rocket Pharma

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

5 Medical Outperformers That Might Lose Steam in 2021

BioNTech SE

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

Denali Therapeutics (DNLI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced biomarker proof of concept was achieved for its Transport Vehicle (TV) technology in a Phase 1/2 study of ETV:IDS (DNL310) for the potential treatment of Hunter syndrome (MPS II). Denali's TV platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration.

Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, will host a virtual R&D Day webinar today highlighting progress across the Company’s broad and diverse biotherapeutics portfolio enabled by its BBB transport vehicle (TV) platform. The webinar will begin at 1:00 p.m. Eastern Time and can be accessed here.

Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the signing of a Definitive LRRK2 Collaboration and License Agreement and a Right of First Negotiation, Option and License Agreement with Biogen, in connection with its previously announced binding provisional collaboration and license agreement for neurodegenerative diseases with Biogen, and the closing of the related common stock purchase agreement.

Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen

— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time —

Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier

SOUTH SAN FRANCISCO, Calif., Aug.  07, 2020  (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights.

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

Denali Therapeutics Inc. (NASDAQ: DNLI) announced early on Thursday that it would be progressing its Parkinson’s treatment into late-stage studies, and investors cheered on this move.

Denali Therapeutics Takes Next Big Step in Treating Parkinson’s

Shares of Denali Therapeutics Inc (NASDAQ: DNLI) are racing toward their 52-week high following a clinical pipeline update concerning the company's Parkinson's disease pipeline.

Why Shares of Denali Therapeutics Are Skyrocketing

SOUTH SAN FRANCISCO, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for treatment of neurodegenerative diseases, today announced that DNL151 has been selected to progress into late stage studies in Parkinson’s disease patients with a kinase activating mutation in LRRK2 and in sporadic Parkinson’s disease patients.

Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients

News for Denali Therapeutics Stock (DNLI)